Extended Data Fig. 2: Distribution and quantitative analysis of Gluc25-S-aPD-L1 in GL261 tumour regions with high and low GLUT1 levels. | Nature Biomedical Engineering

Extended Data Fig. 2: Distribution and quantitative analysis of Gluc25-S-aPD-L1 in GL261 tumour regions with high and low GLUT1 levels.

From: Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma

Extended Data Fig. 2

a,b, Fluorescence images of GLUT1-rich areas (a) and GLUT1-low areas (b) in GL261 tumour sections stained with Alexa Fluor 647-labelled Gluc25-S-aPD-L1 (cyan), anti-CD31 antibody (red), anti-GLUT1 antibody (green) and DAPI (blue). 6 GLUT1-rich areas and 6 GLUT1-low areas from sections of 3 different tumours were selected. Scale bar, 100 μm. c, Blood vessel density and GLUT1 density in GLUT1-rich areas and GLUT1-low areas. d, Co-localization rate of blood vessel and GLUT1 in GLUT1-rich areas and GLUT1-low areas. e, Fluorescence intensity of Alexa Fluor 647-labelled Gluc25-S-aPD-L1 in GLUT1-rich areas and GLUT1-low areas. Data are means ± s.e.m. (n = 6). Statistical significance was calculated by student’s t-test.

Back to article page